Clinical Trials Logo

Clinical Trial Summary

This is a single-center randomized crossover trial. The investigators will target completion of 15 adults (age 18-65 years) with Type 1 Diabetes who use an insulin pump. After completion of the Screening Visit, each subject will participate in a 28-day at home Data Collection Period while using their personal insulin pump, a personal glucometer, a study CGM, and a study activity tracker (i.e., Fitbit). This data collection period may be extended to obtain to gather more days of quality data, if needed per principal investigator judgement.

Once the data has been collected and processed, subjects will participate in two 24-hour admissions (Experimental and Control Admission) in a semi-controlled environment (i.e., hotel), performed in the assigned random order. During both admissions, subjects will use the personal insulin pump and glucometer, and a study CGM. The exercise session will consist of three 15-minute bouts of moderate-intensity exercise (i.e., stationary bicycle). Subjects will be provided a controlled dinner; the SI-informed bolus calculator will be used in the Experimental Admission while standard therapy will be used in the Control Admission. Subjects will then be observed overnight and discharged in the following morning.


Clinical Trial Description

Individuals with Type 1 Diabetes (T1D) require exogenous insulin to keep their blood glucose concentration in a safe euglycemic range, because of the absent internal insulin secretion caused by the autoimmune destruction of pancreatic beta-cells. As a consequence, the quality of glycemic control in T1D is heavily dependent on multiple daily treatment decisions by the patients, which are complicated by a wide variety of factors influencing insulin demand (e.g., circadian rhythms, physical activity, food, stress, etc.). Insulin sensitivity (SI) is a key metabolic parameter in diabetes as it informs on how sensitive the body is to the effects of insulin. In general, if someone has higher SI, the amount of insulin required to lower his blood glucose levels is smaller than that needed by someone who has low sensitivity. However, SI levels within the same person are not constant, and fluctuations of SI happen very frequently in the life of subjects with diabetes, making insulin dosing very difficult to tune.

In this context, the aim of this research project is to develop an SI-informed insulin bolus calculator, with the aim of tailoring the insulin dose to the individual's insulin need at the time the bolus is administered. The SI-informed bolus calculator relies on a Kalman filter-based algorithm which uses continuous glucose monitoring (CGM) data, insulin, and meal records to estimate SI. For each subject, a 24-hour SI profile is computed using data collected over several days of monitoring, and the optimal bolus is then computed by adjusting the standard insulin dose by the ratio between usual SI (from the profile) and real-time SI of the individual at the time the bolus is administered. In this way, if the real-time SI is larger/smaller than the profile SI at that time of day, the insulin dose will be reduced/incremented accordingly.

The study is thus designed as a single-center randomized clinical trial targeting completion of 15 subjects, who will undergo a 28-day at home Data Collection Period followed by two 24-hour admissions (Control and Experimental Admission) performed in random order in a semi-controlled environment (i.e., hotel). The Data Collection is meant to collect data needed to build the 24-hour SI profile for the subject. During the admissions, subjects will undergo a 45-minute afternoon exercise session designed to alter the late-afternoon/evening SI. The dinner meal will then be controlled, and the postprandial glycemic control obtained using the standard bolus calculator (Control Admission) will be compared to the control obtained in response to the optimized SI-informed bolus calculator (Experimental Admission). Metrics computed on CGM data will be compared between the two admissions, including mean blood glucose, time above 250 and 300 mg/dL, time below 70 and 54 mg/dL, and time in 70-180 mg/dL, the primary outcome being the postprandial exposure to hypoglycemia as measured by the Low Blood Glucose Index (a glycemic variability indicator which summarizes the number and extent of low blood glucose events in one single number). If successful, this study will provide a novel, data-oriented paradigm for insulin dosing in T1D. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03709108
Study type Interventional
Source University of Virginia
Contact
Status Completed
Phase N/A
Start date November 19, 2018
Completion date March 31, 2019

See also
  Status Clinical Trial Phase
Completed NCT04476472 - Omnipod Horizon™ Automated Glucose Control System Preschool Cohort N/A
Completed NCT03635437 - Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes Phase 1/Phase 2
Completed NCT04909580 - Decision Coaching for Youth and Parents Considering Insulin Delivery Methods for Type 1 Diabetes N/A
Active, not recruiting NCT00679042 - Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol Phase 3
Completed NCT03293082 - Preschool CGM Use and Glucose Variability in Type 1 Diabetes N/A
Completed NCT04016662 - Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D) Phase 4
Completed NCT02527265 - Afrezza Safety and Pharmacokinetics Study in Pediatric Patients Phase 2
Completed NCT03738865 - G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes Phase 3
Completed NCT03240432 - Wireless Innovation for Seniors With Diabetes Mellitus N/A
Completed NCT03168867 - Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms) N/A
Completed NCT03674281 - The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System N/A
Completed NCT03669770 - Ultrasound Classification and Grading of Lipohypertrophy and Its Impact on Glucose Variability in Type 1 Diabetes
Recruiting NCT03682640 - Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes Phase 2
Recruiting NCT04096794 - Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
Completed NCT02882737 - The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus N/A
Recruiting NCT02745808 - Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1
Completed NCT02596204 - Diabetes Care Transformation: Diabetes Data Registry and Intensive Remote Monitoring N/A
Withdrawn NCT02579148 - Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1
Withdrawn NCT02518022 - How to be Safe With Alcoholic Drinks in Diabetes N/A
Completed NCT02558491 - Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM N/A